Pawelec Graham, Rees Robert C
University of Tuebingen Medical School, Center for Medical Research (ZMF), Germany.
Trends Mol Med. 2002 Dec;8(12):545-6. doi: 10.1016/s1471-4914(02)02430-9.
The application of 'new' and 'recognized' tumour antigens in vaccination strategies that target CD8(+) and CD4(+) T-cell responses, and the mechanisms by which these and other effector cells are activated or respond, were discussed at the second 'Progress in Vaccination Against Cancer' meeting, held at the Nottingham Trent Djanogly Conference Centre, Nottingham, UK, from 18-20 July 2002.
2002年7月18日至20日在英国诺丁汉特伦特贾诺利会议中心举行的第二届“癌症疫苗接种进展”会议上，讨论了“新型”和“已知”肿瘤抗原在针对CD8(+)和CD4(+) T细胞反应的疫苗接种策略中的应用，以及这些效应细胞和其他效应细胞被激活或做出反应的机制。
